Etanercept for Wegener's Granulomatosis
Wegener's Granulomatosis Etanercept Trial (WGET)
Sponsor: FDA Office of Orphan Products Development
This PHASE2/PHASE3 trial investigates Wegener's Granulomatosis and is currently completed. FDA Office of Orphan Products Development leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Jun 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- FDA Office of Orphan Products Development
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
For direct contact, visit the study record on ClinicalTrials.gov .